New Targeted Drug vs Chemotherapy for Resistant Ovarian Cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new targeted drug (SHR-A1811) against standard chemotherapy for ovarian cancer that no longer responds to platinum drugs. It's for people whose tumors have a specific protein called HER2, and who have had limited prior treatments after platinum resistance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old with ovarian, fallopian tube, or primary peritoneal cancer.
- Your cancer got worse or came back within 6 months of finishing platinum chemotherapy (like carboplatin or cisplatin).
- Your tumor must have low to high levels of a protein called HER2 (tested by a central lab).
- You have at least one tumor that shows up on a CT scan (at least 1 cm wide).
- You are healthy enough to be up and about (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new drug, SHR-A1811, for ovarian cancer that came back after responding well to platinum chemo. It is for people with BRCA mutations or HRD positive status who have already tried a PARP inhibitor.
This trial tests a new drug called SHR-A1811 for ovarian cancer. It may help people whose cancer can be measured on scans and who are still well enough to do daily activities.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new targeted drug, SHR-A1921, given alone or with chemotherapy (carboplatin) for people with ovarian cancer that has come back or spread. It aims to see if this combination works better than standard treatments.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.